Pharmacological induction of fetal hemoglobin synthesis using histone deacetylase inhibitors

Hematology. 2004 Jun;9(3):223-33. doi: 10.1080/10245330410001701512.

Abstract

A number of pharmacological agents are currently available for the induction of the fetal hemoglobin (Hb F) to treat the patients with sickle cell disease and beta-thalassemia. In the present review, we summarized the investigation and development of these Hb F-inducing agents and introduced histone deacetylase inhibitors as the new strategy to induce Hb F to treat the hemoglobin disorders

Publication types

  • Research Support, U.S. Gov't, P.H.S.
  • Review

MeSH terms

  • Anemia, Sickle Cell / drug therapy
  • Azacitidine / therapeutic use
  • Enzyme Inhibitors / therapeutic use*
  • Fetal Hemoglobin / biosynthesis*
  • Histone Deacetylase Inhibitors*
  • Humans
  • Hydroxyurea / therapeutic use
  • beta-Thalassemia / drug therapy

Substances

  • Enzyme Inhibitors
  • Histone Deacetylase Inhibitors
  • Fetal Hemoglobin
  • Azacitidine
  • Hydroxyurea